Business Context and Reporting Period
This Form 8-K Current Report was filed by Protara Therapeutics, Inc. (Nasdaq: TARA) on February 2, 2021, covering events occurring on January 29, 2021. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements rather than financial performance results.
Material Changes
The material change disclosed is the appointment of Cynthia Smith as a Class III director and a member of the Compensation Committee, effective January 29, 2021. Her term is set to last until the Company's 2023 annual meeting of stockholders.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the details of Ms. Smith's appointment and compensation package under the Company's Amended and Restated Non-Employee Director Compensation Policy:
- Cash Compensation: Annual cash compensation of $40,000 for Board service and $6,000 for Compensation Committee service, payable in quarterly installments and pro-rated based on days served.
- Equity Grants:
- Stock option to purchase 18,000 shares, vesting in equal monthly installments over three years.
- Stock option to purchase 3,750 shares, vesting in equal monthly installments over one year, with full vesting guaranteed by the 2021 annual meeting.
- Indemnification: The Company entered into a standard indemnification agreement with Ms. Smith.
No financial guidance, outlook, risks, or contingencies were disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 21,750 new stock options granted to Ms. Smith.
- Review the Company's Amended and Restated Non-Employee Director Compensation Policy to confirm the pro-ration calculation for the current fiscal year.
- Confirm the date of the 2021 annual meeting of stockholders to validate the accelerated vesting condition for the 3,750-share option grant.
- Check for any subsequent filings regarding Ms. Smith's background or potential conflicts of interest not detailed in this 8-K.